ATB-101

ATB-101
Product Description

[ARB+SGLT-2i Fixed Dose Combination] – In process of Phase 3 clinical trial on approx. 250 patients
1. The first Fixed Dose Combination treating hypertension and type 2 diabetes by a tablet in the world

2. Expect the synergistic effect in the treatment of hypertension though minor blood pressure lowering effect of the SGLT-2 inhibitor 

3. Expect indication expansion to CKD (Chronic Kidney Disease) and HF (Heart Failure) by the synergistic mechanism of ARB and SGLT-2i

Read more Show less

Autotelic Bio

  • KR
  • 2021
    On CPHI since
  • 25 - 49
    Employees
Company types
Manufacturer/Innovator
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Cardiovascular Health
More specifications Fewer specifications

Autotelic Bio

  • KR
  • 2021
    On CPHI since
  • 25 - 49
    Employees
Company types
Manufacturer/Innovator
View company profile

More Products from Autotelic Bio (2)

  • ATB-330

    Product ATB-330

    [ALK5 inhibitor / Small Molecule / Develop for IPF and Fibrosis) – Complete to derivate the lead compound

    1. Confirm the highest ALK5 selectivity with superior efficacy and PK profile through in-vivo tests compared to competitors (small molecule new drugs) 
    ...
  • ATB-301

    Product ATB-301

    [TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib

    1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients 

    2. Confirm the suppression of IL-2’s side effect in combinati...

Autotelic Bio resources (1)